ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Preclinical data show that the inhibition of NADPH oxidases is an effective strategy to block the signalling cascades initiated by the BCR-ABL and FLT3-ITD oncokinases in CML and AML cells, respectively.